SCHEMBL4507809

SCHEMBL4507809

COc1ccc2ncc(NC(=O)O)c(Cl)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
MALT1 Q9UDY8 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 2/20 0.37
TSHR P16473 3/20 0.37
PABPC1 P11940 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 2/20 0.37
HTT P42858 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PDE10A Q9Y233 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14361227 0.84 EGFR (0.41) MAPTMAPK1MEN1KMT2AKDM4E
SCHEMBL2034625 0.80 POLB (0.49) MEN1KMT2AKDM4EPABPC1SMN1; SMN2
SCHEMBL3272779 0.76 NNMT (0.50) KDM4EPDE10ANNMTPTPN11
SCHEMBL28867703 0.75 PTPN11 (0.38) PDE10APTPN11KCNH2
SCHEMBL621738 0.74 KMT2A (0.51) MAPTMAPK1MEN1KMT2AKDM4E
SCHEMBL5261837 0.74 EGFR (0.37) POLBTDP1PDE10ANNMTKCNH2
SCHEMBL29050321 0.74 POLB (0.42) MEN1KMT2AKDM4EPABPC1ALDH1A1
SCHEMBL4507986 0.73 MAP4K4 (0.41) PDE10APTPN11KCNH2PIK3CG
SCHEMBL14905348 0.73 EGFR (0.41) PDE10AHDAC3APPACHEHDAC1
SCHEMBL4502318 0.73 KCNH2 (0.43) MEN1KMT2APABPC1PTPN11KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 US disclosed
EP-1891078-A1 AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2008-02-27 EP disclosed
WO-2006125974-A1 AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity AAAS, AMPD2, AMPD3 MAPT 3324/4885MAPK1 3309/4885MALT1 2963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.